Sarepta Forms Strategic Advisory Board
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics Inc., a developer of RNA-targeted therapies, has formed a strategic and scientific advisory board (SSAB) with three key appointments: Dr Louis Kunkel, Dr Beverly Davidson, and Dr Jeffrey Chamberlain. The SSAB will work closely with Sarepta's management team to advance the company's platform technology in Duchene muscular dystrophy, identify multiple new applications for Sarepta's proprietary PMO chemistry in the neuromuscular rare disease and infectious disease areas, as well as provide insight on novel technologies to complement the company's pipeline.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.